Sabra Health Care REIT enters its April 30 earnings print with one of the more meaningful short positions in the healthcare REIT space, while options traders have recently turned more cautious than usual — a combination worth watching heading into the release.
Short sellers have been adding exposure through April. SI climbed 10% over the past month to reach 11.1% of the free float, a level that ranks in just the 2nd percentile of the ORTEX universe for short score rank. The ORTEX short score holds near 69, consistent with sustained bearish positioning. Despite that, the borrow market tells a less stressful story: cost to borrow is a modest 0.48%, down around 9% on the month, and availability remains well-supplied — nothing in the lending data points to a squeeze dynamic developing ahead of the print.
Options positioning has turned defensive into the release. The put/call ratio moved to 0.48, running roughly 1.6 standard deviations above its 20-day average of 0.35. That shift from a very call-heavy posture in mid-March — when PCR was below 0.17 — to a more balanced setup today suggests some hedging activity has come in as the date approached. The stock itself has recovered from early-April weakness, adding nearly 4% on the week to close at $20.35, broadly in line with peers: CTRE gained 3.5% on the week, rose 3.2%, and added 3.8%, while diverged sharply to the downside, off 8%.
The analyst debate largely maps onto the two known risks. Bulls point to improving occupancy, recovering seniors housing managed performance, and above-average RIDEA exposure as structural tailwinds. Bears flag high leverage relative to peers, unpredictable operator performance amid an inflationary cost environment, and a valuation that was already near the top of its decade-long range. The recent analyst tone has been constructive on price targets — Wells Fargo raised its target to $22 in late March, maintaining Overweight — but the consensus remains a cautious hold across seven analysts, with no fresh upgrades in the lead-up. Insider activity since January has been net selling, led by a CFO disposal of roughly $905k in early January, though the 90-day net figure is skewed positive by equity award grants rather than open-market buying.
The print will test whether Sabra's occupancy momentum is translating into financial performance that can justify a stock now trading near analyst price targets, while the market weighs continued operator risk against the wider REIT recovery story.
See the live data behind this article on ORTEX.
Open SBRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
